CytoDyn's Leronlimab Suffers Refuse To File Letter; US FDA Concerned About Dosing, Manufacturing

US FDA declines to review the CCR5 antagonist for use in highly treatment-experienced HIV patients. Safety data from an ongoing study should be sufficient to address the agency’s concerns about the higher 700mg dose, CytoDyn management says, but FDA also has questions about the production of the self-injectable syringes.

Stop sign
A refuse to file letter has stopped review of leronlimab by the US FDA until CytoDyn can provide more data.

CytoDyn, Inc. is pushing to develop the CCR5 antagonist leronlimab for a wide range of indications, including HIV, cancer and COVID-19, but the effort has hit a roadblock at the US Food and Drug Administration. The company announced on 13 July that it has received a refusal to file letter from the FDA for its first biologics license application for leronlimab for highly treatment experienced HIV patients.

The update casts more doubts on CytoDyn's development plan for leronlimab, which has already faced some stumbling blocks. The company...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Product Reviews

More from Pink Sheet

Adaptive Clinical Trials Require ‘Clear And Compelling Justification’

 
• By 

A draft international guideline on using adaptive trial designs says sponsors should provide a clear rationale for using such designs to address the potential ‘tension’ between the confirmatory nature of late-stage trials and the flexibility introduced by mid-trial adaptations.

What Pharma Needs To Know About Vietnam’s Drug Registration Reforms

 

Newly introduced rules for streamlining drug registration in Vietnam are said to present both opportunities and challenges for stakeholders.

European Industry Calls For Support As It Juggles Multiple Challenges

 
• By 

At Medicines for Europe’s legal and annual conferences in Brussels last week, multiple key issues competed for attention, giving the generics and biosimilars industry plenty to think about at a critical time for EU pharma reform.